[
    {
        "question": "Half-life of basiliximab is:-",
        "exp": "Half life of basiliximab is 7 days. Basiliximab* This is anti CD-25 antibody with higher affinity for the IL-2 receptor, but shoer plasma t 1/2 (1 week).* It is used to prevent renal and other transplant rejection reaction.* It can cause anaphylactic reactions and promote oppounistic infection.",
        "cop": 1,
        "opa": "7 days",
        "opb": "7 hours",
        "opc": "15 days",
        "opd": "24 hours",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "780c5d75-8009-4c14-b9c0-d63c79a48abe",
        "choice_type": "single"
    },
    {
        "question": "Which of the following statements is false regarding bedaquiline?",
        "exp": "Bedaquiline is a new tubercular drug which inhibits mycobacterial ATP synthase. Resistance occurs by mutation to ATP synthase and efflux pimp. Terminal half life is high about 160 days. Adverse effects are QR prolongation and hepatotoxicity. It is indicated for MDR TB and XDR TB. Other drugs are Delaminid and Pretomanid. So first option is better one.",
        "cop": 1,
        "opa": "Inhibits mycobacterial cell wall synthesis",
        "opb": "Causes QT prolongation",
        "opc": "Half-life is very long",
        "opd": "Indicated for MDR TB and XDR TB",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "95890342-07d4-4020-ae96-2df9a2f57988",
        "choice_type": "multi"
    },
    {
        "question": "Deprescription of PPIs can be done in all except:-",
        "exp": "Deprescription of PPIs is Indicated Not indicated Mild to moderate esophagitits Barrett's esophagus GERD Chronic NSAID user with bleeding risk PUD (NSAID OR H. PYLORI) Severe esophagitis ICU stress ulcer prophylaxis Documented history of bleeding GI ulcer. Uncomplicated H. pylori Upper GI symptoms without endoscopy",
        "cop": 1,
        "opa": "40 year old with Barret's esophagus",
        "opb": "40 year old with GERD",
        "opc": "45 year old with NSAID induced ulcer",
        "opd": "Stress ulcer in ICU patient",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "494df3b0-8436-456c-af64-3164f976c6cf",
        "choice_type": "multi"
    },
    {
        "question": "Which statin is not metabolized by CYP3. A4?",
        "exp": "Pravastatin causes minimum drug interactions, minimum food interactions and minimum risk of myopathy. They also decreases amount of fibrinogen and it is not metabolised by CYP3. A4.",
        "cop": 4,
        "opa": "Lovastatin",
        "opb": "Simvastatin",
        "opc": "Atorvastatin",
        "opd": "Pravastatin",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "5a3fb07e-9607-44b4-98d6-e9e2046b8ce4",
        "choice_type": "single"
    },
    {
        "question": "Which antimicrobial drug possesses anti-inflammatory and immunomodulatory propeies?",
        "exp": "Tacrolimus chemically macrolides have strong anti inflammatory and immunomodulatory actions and are widely used as an immune suppressant whereas other macrolides are anti microbial.",
        "cop": 2,
        "opa": "Fluoroquinolones",
        "opb": "Macrolides",
        "opc": "Tetracyclines",
        "opd": "Acyclovir",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "4b57ba5f-ab7c-4029-8808-8cfb57b6d3b6",
        "choice_type": "single"
    },
    {
        "question": "Mechanism of resistance of tetracyclines is due to?",
        "exp": "Mechanism of Resistance Examples Enzymatic breakdown A: Aminoglycosides B: Beta lactams C: Chloramphenicol Decreased permeability Aminoglycosides Efflux pumps Tetracyclines Altered metabolic pathway Sulfonamides Altered target MRSA Vancomycin, Fluoroquinolones",
        "cop": 1,
        "opa": "Drug efflux mechanism",
        "opb": "Development of inactivating enzymes",
        "opc": "DNA methylation",
        "opd": "Cell wall alteration",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "c0a8aae7-c002-49e3-9df0-e06dd66e6d8c",
        "choice_type": "multi"
    },
    {
        "question": "Which of the following combinations can result in severe toxicity due to inhibition of cytochrome 450 enzymes?",
        "exp": "Atorvastatin is a statin which is anti dyslipidemic agent and itraconazole is an azole which is anti fungal which are metabolised by Cytochrome 450 oxidase enzyme. Due to inhibition of Cytochrome enzyme toxicity occurs. So third option is a better one.",
        "cop": 3,
        "opa": "Amiodarone + phenytoin",
        "opb": "Carbamazepine + phenytoin",
        "opc": "Atorvastatin + Itraconazole",
        "opd": "Phenytoin + Rifampin",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "9eca0708-c7d5-4b63-aeac-e52086920e05",
        "choice_type": "single"
    },
    {
        "question": "Which of the following decreases defibrillation threshold:-",
        "exp": "Defibrillation threshold is minimum amount of electric current required ventricular fibrillation. DEFIBRILLATION THRESHOLD INCREASE Amiodarone Atropine Diltiazem Verapamil DECREASES Sotalol So 3rd option is the answer.",
        "cop": 3,
        "opa": "Amiodarone",
        "opb": "Verapamil",
        "opc": "Sotalol",
        "opd": "Diltiazim",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "734b9d83-5030-4732-8f6f-6462579df3f7",
        "choice_type": "single"
    },
    {
        "question": "Bile acid resins are used as anti-dyslipidemic drugs. How much decrease in LDL cholesterol and how much increase in HDL cholesterol can occur with their use?",
        "exp": "Mostly anti dyslipidemic agents decreases LDL about 15% but statins are the impoant one since they decrease LDL up to 50% since they are maximum LDL lowering agents whereas HDL is increased up to 30% by Fibrates whereas others increase by 3-5%. The only agent which significantly decreases Triglycerides are Fibrates. So 2nd option is the better option.",
        "cop": 2,
        "opa": "5-10% decrease in LDL-C and 3-5% increase in HDL-C",
        "opb": "15-25% decrease in LDL-C and 3-5% increase in HDL-C",
        "opc": "3-5% decrease in LDL-C and 15-25% increase in HDL-C",
        "opd": "25-35% decrease in LDL-C and 5-10% increase in HDL-C",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "a9f77879-2e3e-4c8d-911f-268642451e02",
        "choice_type": "single"
    },
    {
        "question": "A patient on Bilonatumomab for refractory B cell All is now resistance to the drug. Which drug to be used:-",
        "exp": "Drug Mechanism Use Vorinostat HDAC inhibitor Cutaneous T cell lymphoma Brentuximab Man against CD30 Hodgkin lymphoma Pembrolizumab PD-1 Melanoma Lung Cancer Head and neck cancer Tisagenlecleucel Ca therapy ALL Blinatumomab Bispecific t-cell engages ( targets CD19 and CD3) ALL",
        "cop": 3,
        "opa": "Vorinostat",
        "opb": "Brentuximab",
        "opc": "Pembrolizumab",
        "opd": "Tisagenlecleucel",
        "subject_name": "Pharmacology",
        "topic_name": "JIPMER 2019",
        "id": "09e0a7d8-6a3b-41be-8200-b32900c38d06",
        "choice_type": "multi"
    }
]